Good News: Beilu Pharmaceutical's Jiuwei Zhenxin Granules Included in 18 Industry Consensus Guidelines

The company's product, Jiuwei Zhenxin Granules, has been included in the "Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Bipolar Depression in Zhejiang Province" and the "Expert Consensus on Traditional Chinese Medicine Diagnosis and Treatment of Tumor-Related Depression." It is recommended for patients with depression of the spleen and heart deficiency syndrome and has been included in 18 industry guidelines/consensuses.

The "Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Bipolar Depression in Zhejiang Province" was compiled by the Bipolar Disorder Group of the Zhejiang Provincial Association of Integrated Traditional Chinese and Western Medicine in March 2022 and officially published in the Journal of Psychiatry.

Bipolar disorder (also known as manic-depressive disorder) generally refers to a type of mood disorder characterized by both manic or hypomanic episodes and depressive episodes. The worldwide lifetime prevalence of bipolar disorder is as high as 5.5% to 7.8%. Most forms of bipolar disorder involve depressive episodes, known as bipolar depression, which account for two-thirds of all episodes.

The consensus points out that Western medicine treatment for bipolar depression mainly relies on mood stabilizers, which have a slow onset of action and less-than-ideal treatment outcomes. Therefore, the combination of traditional Chinese and Western medicine is beneficial in changing the current treatment situation. In particular, evidence-based medicine studies on common TCM syndrome patterns of bipolar depression have confirmed that the combined treatment of traditional Chinese and Western medicine can improve efficacy without increasing the risk of manic episodes, making it an effective approach for treating bipolar depression.

The consensus recommends the use of Jiuwei Zhenxin Granules for patients with bipolar depression of the spleen and heart deficiency syndrome.

In January 2023, the "Expert Consensus on Traditional Chinese Medicine Diagnosis and Treatment of Tumor-Related Depression" was officially published, jointly compiled by the Hematology Branch of the Chinese Association of Traditional Chinese Medicine, the Hematology Branch of the Chinese Ethnic Medicine Association, the Chinese Society of Integrated Traditional Chinese and Western Medicine Oncology, and the Oncology Branch of the Beijing Society of Integrated Traditional Chinese and Western Medicine.

Data shows that the incidence of tumor-related depression in China is as high as 25% to 75%, but less than 10% of patients are accurately diagnosed. Tumor-related depression is a disease that is difficult to detect during the occurrence, diagnosis, and treatment of tumors but significantly affects the patient's quality of life and treatment outcomes. Its occurrence and progression are closely related to psychological factors, cancer-related pain, fatigue, sleep disorders, surgical trauma, radiotherapy, chemotherapy, and other factors.

According to traditional Chinese medicine, tumor-related depression is based on the etiology and pathogenesis of malignant tumors. It is caused by liver depression from anger, spleen damage from overthinking, heart damage from excessive mental strain, resulting in dysfunction of the organs, as well as a psychosomatic disorder characterized by the disorder of qi and blood. The degree of depression is closely related to the dysfunction of the organs.

To improve the quality of life of tumor patients and reduce the risk of sudden death, the consensus recommends intervention treatments for tumor-related depression, including non-drug therapy, syndrome differentiation treatment, and traditional Chinese patent medicine such as Jiuwei Zhenxin Granules.

Jiuwei Zhenxin Granules is an innovative Chinese patent medicine that has obtained explicit approval for the indication of "generalized anxiety disorder" in China. Since its market launch, it has been widely used in the treatment of anxiety patients and has been included in 18 industry guidelines/consensuses.